Demographic data in the full study and interview populations
| Control group (n=75) | Intervention (n=75) | Total (n=150) | Interview (n=10) | ||
| Ethnicity | White | 62 (83%) | 66 (88%) | 128 (85%) | 9 (90%) |
| Asian/Asian British | 2 (3%) | 1 (1%) | 3 (2%) | ||
| Black/Black British | 4 (5%) | 3 (4%) | 7 (5%) | 1 (10%) | |
| Mixed | 1 (1%) | 2 (3%) | 3 (2%) | ||
| Other | 6 (8%) | 3 (4%) | 9 (6%) | ||
| Age | <40 | 14 (19%) | 14 (19%) | 28 (19%) | 1 (10%) |
| 40–60 | 35 (47%) | 34 (45%) | 69 (46%) | 6 (60%) | |
| >60 | 26 (35%) | 27 (36%) | 53 (35%) | 3 (30%) | |
| Diagnosis | Cervical | 14 (19%) | 16 (21%) | 30 (20%) | 2 (20%) |
| Endometrial | 24 (32%) | 27 (36%) | 51 (34%) | 4 (40%) | |
| Ovarian | 29 (39%) | 27 (36%) | 56 (37%) | 3 (30%) | |
| Vulval | 8 (11%) | 5 (7%) | 13 (9%) | 1 (10%) | |
| Primary treatment | Chemotherapy | 9 (12%) | 9 (12%) | 18 (12%) | 1 (10%) |
| Radiotherapy | 9 (12%) | 10 (13%) | 19 (13%) | 2 (20%) | |
| Surgery | 57 (76%) | 56 (75%) | 113 (75%) | 7 (70%) | |
| FIGO stage | I | 39 (52%) | 36 (48%) | 75 (50%) | 1 (10%) |
| II | 19 (25%) | 23 (31%) | 42 (28%) | 6 (60%) | |
| III | 17 (23%) | 16 (21%) | 33 (22%) | 3 (30%) | |
| Weeks from last treatment | Mean | 20.52 | 20.21 | 20.21 | 10.4 |
| Minimum | 0 | 0 | 0 | 2 | |
| Maximum | 178 | 44 | 178 | 23 |
Interview: those participants who completed the study in the intervention arm and were purposively sampled and invited to attend a semi-structured interview exploring their experiences and impact of the intervention.
FIGO: International Federation of Gynaecology tumour stages I–III.